News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The product will be launched in March 2024
Eugia Pharma Specialities restarts production at terminally sterilized product lines
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The observations do not pose any risk to site's compliance standards or its business continuity
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Subscribe To Our Newsletter & Stay Updated
